Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.

T, Facon; S, Kumar; T, Plesner; RZ, Orlowski; P, Moreau; N, Bahlis; S, Basu; H, Nahi; C, Hulin; H, Quach; H, Goldschmidt; M, O'Dwyer; A, Perrot; CP, Venner; K, Weisel; JR, Mace; N, Raje; M, Attal; M, Tiab; M, Macro; L, Frenzel; X, Leleu; T, Ahmadi; C, Chiu; J, Wang; Rampelbergh R, Van; CM, Uhlar; R, Kobos; M, Qi; SZ, Usmani

doi:10.1056/nejmoa1817249

Public

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.

Shared by NobleBlocks on May 1, 2019 • 12:00 AM UTC

Authors:

Facon T

Kumar S

Plesner T

Abstract

Background Lenalidomide plus dexamethasone is a standard treatment for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation. We sought to determine whether the addition of daratumumab would significantly reduce the risk of disease progression or ...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!